These subgroups increase insight in biological tumor behavior based on molecular signature beyond current morphological classification.3 Patients with TP53-altered tumors have the worst outcome, representing 15% of all EC diagnoses and responsible for 50% to 70% of all EC-related mortality.4,5. Here, TP53 is linked to neoplasm.